Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size, Share, Growth, and Industry Analysis, By Type (XIFAXAN, Viberzi, Lotronex, Other), By Application (Hospitals, Clinics, Others), Regional Insights and Forecast to 2035
Table of Content
1 Market Overview
1.1 Product Definition and Market Characteristics
1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size
1.3 Market Segmentation
1.4 Regulatory Environment
2 Industry Chain Analysis
2.1 Industry Chain Analysis
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Materials Analysis
2.2.1 Key Raw Materials Introduction
2.2.2 Key Suppliers of Raw Materials
2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Mode and Production Process
2.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Mode Analysis
2.3.2 Production Process Analysis
2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Cost Structure Analysis
2.4.1 Manufacturing Cost Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
2.4.2 Raw Material Cost of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
2.4.3 Labor Cost of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
2.5 Market Channel Analysis
2.6 Major Downstream Customers Analysis
2.7 Alternative Product Analysis
3 Market Dynamics
3.1 Market Drivers
3.2 Market Constraints and Challenges
3.3 Emerging Market Trends
3.4 PESTEL Analysis
3.5 Consumer Insights Analysis
3.6 Impact of Russia and Ukraine War
4 Market Competitive Landscape
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Manufacturer (2020-2026)
4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume and Market Share by Manufacturer (2020-2026)
4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Manufacturer (2020-2026)
4.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
4.5 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Base Distribution and Headquarters
4.6 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Offered and Application
4.7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation and Trends
4.7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate
4.7.2 Global Top 3 and Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue
4.8 Industry News
4.8.1 Key Product Launch News
4.8.2 Mergers & Acquisitions, Expansion Plans
5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Historical Development by Geographic Region (2020-2026)
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Historical Sales Volume by Geographic Region (2020-2026)
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Historical Revenue by Geographic Region (2020-2026)
5.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Country (2020-2026)
5.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2020-2026)
5.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2020-2026)
5.3.3 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.3.4 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Country (2020-2026)
5.4.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2020-2026)
5.4.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2020-2026)
5.4.3 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4.4 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4.5 United Kingdom Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4.6 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4.7 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4.8 Poland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Country (2020-2026)
5.5.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2020-2026)
5.5.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2020-2026)
5.5.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5.5 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5.6 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5.7 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5.8 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.6 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Country (2020-2026)
5.6.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2020-2026)
5.6.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2020-2026)
5.6.3 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.6.4 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.7 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Country (2020-2026)
5.7.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2020-2026)
5.7.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2020-2026)
5.7.3 GCC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.7.4 South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Historical Development by Product Type (2020-2026)
6.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Definition by Type
6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume by Product Type (2020-2026)
6.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Revenue by Product Type (2020-2026)
6.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Price by Product Type (2020-2026)
6.5 Global Historical Sales Volume, Revenue and Growth Rate by Product Type (2020-2026)
6.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of XIFAXAN (2020-2026)
6.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Viberzi (2020-2026)
6.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Lotronex (2020-2026)
6.5.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Other (2020-2026)
7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Historical Development by End User (2020-2026)
7.1 Downstream Market Overview
7.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume by End User (2020-2026)
7.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Revenue by End User (2020-2026)
7.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Price by End User (2020-2026)
7.5 Global Historical Sales Volume, Revenue and Growth Rate by End User (2020-2026)
7.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Hospitals (2020-2026)
7.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Clinics (2020-2026)
7.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Others (2020-2026)
8 Leading Companies Profiles
8.1 Astellas Pharmaceuticals
8.1.1 Astellas Pharmaceuticals Corporation Information
8.1.2 Astellas Pharmaceuticals - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.1.3 Astellas Pharmaceuticals Performance Analysis (2020-2026)
8.1.4 Astellas Pharmaceuticals Business and Markets Served
8.1.5 Astellas Pharmaceuticals Recent Developments
8.2 Pharscin Pharma
8.2.1 Pharscin Pharma Corporation Information
8.2.2 Pharscin Pharma - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.2.3 Pharscin Pharma Performance Analysis (2020-2026)
8.2.4 Pharscin Pharma Business and Markets Served
8.2.5 Pharscin Pharma Recent Developments
8.3 Sebela Pharmaceuticals
8.3.1 Sebela Pharmaceuticals Corporation Information
8.3.2 Sebela Pharmaceuticals - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.3.3 Sebela Pharmaceuticals Performance Analysis (2020-2026)
8.3.4 Sebela Pharmaceuticals Business and Markets Served
8.3.5 Sebela Pharmaceuticals Recent Developments
8.4 Amneal Pharms
8.4.1 Amneal Pharms Corporation Information
8.4.2 Amneal Pharms - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.4.3 Amneal Pharms Performance Analysis (2020-2026)
8.4.4 Amneal Pharms Business and Markets Served
8.4.5 Amneal Pharms Recent Developments
8.5 Allergan
8.5.1 Allergan Corporation Information
8.5.2 Allergan - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.5.3 Allergan Performance Analysis (2020-2026)
8.5.4 Allergan Business and Markets Served
8.5.5 Allergan Recent Developments
8.6 Bausch Health
8.6.1 Bausch Health Corporation Information
8.6.2 Bausch Health - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.6.3 Bausch Health Performance Analysis (2020-2026)
8.6.4 Bausch Health Business and Markets Served
8.6.5 Bausch Health Recent Developments
9 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Product Type and End User (2026-2033)
9.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Product Type (2026-2033)
9.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of XIFAXAN (2026-2033)
9.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Viberzi (2026-2033)
9.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Lotronex (2026-2033)
9.1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Other (2026-2033)
9.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by End User (2026-2033)
9.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Hospitals (2026-2033)
9.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Clinics (2026-2033)
9.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Others (2026-2033)
10 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Geographic Region (2026-2033)
10.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume and Revenue Forecast by Geographic Region (2026-2033)
10.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.2.1 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.2.2 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.1 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.2 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.3 United Kingdom Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.4 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.5 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.6 Poland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.3 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.4 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.5 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.6 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5.1 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5.2 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6.1 GCC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6.2 South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
11 Appendix
11.1 Methodology
11.2 Research Data Source
11.2.1 Secondary Data
11.2.2 Primary Data
11.2.3 Market Size Estimation
11.2.4 Legal Disclaimer
1 Market Overview
1.1 Product Definition and Market Characteristics
1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size
1.3 Market Segmentation
1.4 Regulatory Environment
2 Industry Chain Analysis
2.1 Industry Chain Analysis
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Materials Analysis
2.2.1 Key Raw Materials Introduction
2.2.2 Key Suppliers of Raw Materials
2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Mode and Production Process
2.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Mode Analysis
2.3.2 Production Process Analysis
2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Cost Structure Analysis
2.4.1 Manufacturing Cost Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
2.4.2 Raw Material Cost of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
2.4.3 Labor Cost of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
2.5 Market Channel Analysis
2.6 Major Downstream Customers Analysis
2.7 Alternative Product Analysis
3 Market Dynamics
3.1 Market Drivers
3.2 Market Constraints and Challenges
3.3 Emerging Market Trends
3.4 PESTEL Analysis
3.5 Consumer Insights Analysis
3.6 Impact of Russia and Ukraine War
4 Market Competitive Landscape
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Manufacturer (2020-2026)
4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume and Market Share by Manufacturer (2020-2026)
4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Manufacturer (2020-2026)
4.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
4.5 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Base Distribution and Headquarters
4.6 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Offered and Application
4.7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation and Trends
4.7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate
4.7.2 Global Top 3 and Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue
4.8 Industry News
4.8.1 Key Product Launch News
4.8.2 Mergers & Acquisitions, Expansion Plans
5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Historical Development by Geographic Region (2020-2026)
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Historical Sales Volume by Geographic Region (2020-2026)
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Historical Revenue by Geographic Region (2020-2026)
5.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Country (2020-2026)
5.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2020-2026)
5.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2020-2026)
5.3.3 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.3.4 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Country (2020-2026)
5.4.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2020-2026)
5.4.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2020-2026)
5.4.3 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4.4 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4.5 United Kingdom Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4.6 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4.7 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.4.8 Poland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Country (2020-2026)
5.5.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2020-2026)
5.5.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2020-2026)
5.5.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5.5 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5.6 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5.7 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.5.8 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.6 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Country (2020-2026)
5.6.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2020-2026)
5.6.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2020-2026)
5.6.3 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.6.4 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.7 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Country (2020-2026)
5.7.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Country (2020-2026)
5.7.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2020-2026)
5.7.3 GCC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
5.7.4 South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue and Growth (2020-2026)
6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Historical Development by Product Type (2020-2026)
6.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Definition by Type
6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume by Product Type (2020-2026)
6.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Revenue by Product Type (2020-2026)
6.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Price by Product Type (2020-2026)
6.5 Global Historical Sales Volume, Revenue and Growth Rate by Product Type (2020-2026)
6.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of XIFAXAN (2020-2026)
6.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Viberzi (2020-2026)
6.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Lotronex (2020-2026)
6.5.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Other (2020-2026)
7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Historical Development by End User (2020-2026)
7.1 Downstream Market Overview
7.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume by End User (2020-2026)
7.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Revenue by End User (2020-2026)
7.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Price by End User (2020-2026)
7.5 Global Historical Sales Volume, Revenue and Growth Rate by End User (2020-2026)
7.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Hospitals (2020-2026)
7.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Clinics (2020-2026)
7.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales Volume, Revenue and Growth Rate of Others (2020-2026)
8 Leading Companies Profiles
8.1 Astellas Pharmaceuticals
8.1.1 Astellas Pharmaceuticals Corporation Information
8.1.2 Astellas Pharmaceuticals - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.1.3 Astellas Pharmaceuticals Performance Analysis (2020-2026)
8.1.4 Astellas Pharmaceuticals Business and Markets Served
8.1.5 Astellas Pharmaceuticals Recent Developments
8.2 Pharscin Pharma
8.2.1 Pharscin Pharma Corporation Information
8.2.2 Pharscin Pharma - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.2.3 Pharscin Pharma Performance Analysis (2020-2026)
8.2.4 Pharscin Pharma Business and Markets Served
8.2.5 Pharscin Pharma Recent Developments
8.3 Sebela Pharmaceuticals
8.3.1 Sebela Pharmaceuticals Corporation Information
8.3.2 Sebela Pharmaceuticals - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.3.3 Sebela Pharmaceuticals Performance Analysis (2020-2026)
8.3.4 Sebela Pharmaceuticals Business and Markets Served
8.3.5 Sebela Pharmaceuticals Recent Developments
8.4 Amneal Pharms
8.4.1 Amneal Pharms Corporation Information
8.4.2 Amneal Pharms - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.4.3 Amneal Pharms Performance Analysis (2020-2026)
8.4.4 Amneal Pharms Business and Markets Served
8.4.5 Amneal Pharms Recent Developments
8.5 Allergan
8.5.1 Allergan Corporation Information
8.5.2 Allergan - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.5.3 Allergan Performance Analysis (2020-2026)
8.5.4 Allergan Business and Markets Served
8.5.5 Allergan Recent Developments
8.6 Bausch Health
8.6.1 Bausch Health Corporation Information
8.6.2 Bausch Health - Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio and Specification
8.6.3 Bausch Health Performance Analysis (2020-2026)
8.6.4 Bausch Health Business and Markets Served
8.6.5 Bausch Health Recent Developments
9 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Product Type and End User (2026-2033)
9.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Product Type (2026-2033)
9.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of XIFAXAN (2026-2033)
9.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Viberzi (2026-2033)
9.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Lotronex (2026-2033)
9.1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Other (2026-2033)
9.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by End User (2026-2033)
9.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Hospitals (2026-2033)
9.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Clinics (2026-2033)
9.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth Rate of Others (2026-2033)
10 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Geographic Region (2026-2033)
10.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume and Revenue Forecast by Geographic Region (2026-2033)
10.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.2.1 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.2.2 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.1 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.2 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.3 United Kingdom Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.4 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.5 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.6 Poland Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.3 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.4 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.5 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.6 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5.1 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5.2 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6.1 GCC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6.2 South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue Forecast and Growth (2026-2033)
11 Appendix
11.1 Methodology
11.2 Research Data Source
11.2.1 Secondary Data
11.2.2 Primary Data
11.2.3 Market Size Estimation
11.2.4 Legal Disclaimer
Our Clients
